Award
National Cancer Institute 5R44CA285206-03
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
Recipient
Cambium Oncology LLC
Award Amount
$1,050,003.00
Ceiling
$1,050,003.00
Awarded
July 17, 2026
Identifier
5R44CA285206-03
Award for developing a novel immunotherapy for acute myeloid leukemia, led by Cambium Oncology LLC and funded by NIH/NCI.
Description
The project aims to develop a first-in-class immunotherapy to improve treatment outcomes for AML patients. The project includes phases for determining potency, anti-leukemia activity, stability, pharmacokinetics, toxicology, and biomarker identification. The project is led by Cambium Oncology LLC, based in Atlanta, GA. The project is funded by the NIH/NCI under award number 5R44CA285206-03 and involves collaboration with the NIH Study Section ZRG1-CDPT-V(13)B.